Brandon Tse
YOU?
Author Swipe
View article: Data from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Data from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Introduction: BRM, a key catalytic subunit of the SWI/SNF chromatin remodeling complex, is a putative tumor susceptibility gene that is silenced in 15% of non–small cell lung cancer (NSCLC). Two novel BRM promoter polymorphisms (BRM-741 an…
View article: Supplementary Table 1 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Supplementary Table 1 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Comparison of Analyzed and Non-Analyzed Data from the PM Cohort. This table was an analysis requested by a reviewer.
View article: Data from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Data from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Introduction: BRM, a key catalytic subunit of the SWI/SNF chromatin remodeling complex, is a putative tumor susceptibility gene that is silenced in 15% of non–small cell lung cancer (NSCLC). Two novel BRM promoter polymorphisms (BRM-741 an…
View article: Supplementary Table 2 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Supplementary Table 2 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Subgroup prognostic analyses of BRM polymorphisms in adjusted Hazard ratios (95% confidence intervals) - each comparison uses wildtype or double wildtype as the reference category.
View article: Supplementary Table 1 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Supplementary Table 1 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Comparison of Analyzed and Non-Analyzed Data from the PM Cohort. This table was an analysis requested by a reviewer.
View article: Supplementary Table 2 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
Supplementary Table 2 from BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Subgroup prognostic analyses of BRM polymorphisms in adjusted Hazard ratios (95% confidence intervals) - each comparison uses wildtype or double wildtype as the reference category.
View article: Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience
Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience Open
When combined with therapeutic plasma exchange (TPE) and immunosuppression, upfront universal administration of caplacizumab was shown to be effective in the management of immune thrombotic thrombocytopenic purpura (iTTP). However, access …
View article: Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection
Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection Open
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease that may be triggered by inflammation, including infection or vaccination. Since the start of the COVID-19 pandemic, several case reports were published on de novo or …
View article: Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab
Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab Open
A 58-year-old woman was hospitalised with a relapse of thrombotic thrombocytopenic purpura (TTP). She was diagnosed with immune TTP 10 years ago and has had two previous relapses. Her first episode was treated with therapeutic plasma excha…
View article: Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review
Evaluating hemostatic thresholds for neuraxial anesthesia in adults with hemorrhagic disorders and tendencies: A scoping review Open
Neuraxial anesthesia can be complicated by spinal or epidural hematoma and may result in permanent neurologic injury. There is a paucity of literature characterizing this serious complication in patients with congenital and acquired hemorr…
View article: Coronavirus-19 and coagulopathy: A Systematic Review [COVID-COAG]
Coronavirus-19 and coagulopathy: A Systematic Review [COVID-COAG] Open
Background Understanding the association between Coronavirus Disease 2019 (COVID-19) and coagulopathy may assist clinical prognostication, and influence treatment and outcomes. We aimed to systematically describe the relationship between h…
View article: Improvement in Hematology Interprofessional Care: Simulation With an Emphasis on Collaboration
Improvement in Hematology Interprofessional Care: Simulation With an Emphasis on Collaboration Open
Simulation is a promising tool for teaching and assessing collaboration within hematology training.
View article: Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment
Longitudinal Health Utilities, Symptoms and Toxicities in Patients with ALK-Rearranged Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Prospective Real-World Assessment Open
Background: Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival of patients with ALK-rearranged (ALK+) non-small-cell lung cancer (NSCLC). Clinical trial data can generally compare drugs in a pair-wise fashion. Real-w…
View article: The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis Open
Background In lung cancer, brain metastases (BM) and their treatment are associated with high economic burden and inferior health-related quality of life. In the era of targeted therapy, real world evidence through health utility scores (H…
View article: Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome
Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome Open
BRM polymorphisms were associated with OS in EAC in this study. Validation studies are warranted.
View article: BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial
BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial Open
Introduction: BRM, a key catalytic subunit of the SWI/SNF chromatin remodeling complex, is a putative tumor susceptibility gene that is silenced in 15% of non–small cell lung cancer (NSCLC). Two novel BRM promoter polymorphisms (BRM-741 an…